Medicare hangs a pretty small carrot for P4P, as Dr. Wes explains:
The implication of this bribery for reporting is significant, since it establishes a measly 1.5% premium on “Pay for Performance” – hardly a robust incentive. For instance, for a 20-minute outpatient follow-up visit that averages a $54 dollar Medicare reimbursement, Medicare is willing to pay an additional $0.81 for us to submit data about the drugs we give the patient. Since the payment isn’t enough to offset the cost in man-hours to supply the data, will the data be complete or accurate?
